

Support a patient. Apply regeneration. Make an impact.

More information and
submission guidelines



As part of its 175-year jubilee, Geistlich has launched a new patient support programme designed to improve access to regenerative dental treatment for patients who would otherwise remain untreated due to financial limitations. The initiative reflects a central principle of regenerative dentistry: the restoration of oral tissues can also restore function, confidence, and quality of life. In daily practice, clinicians frequently encounter patients with clear indications for regenerative therapy whose treatment plans are delayed, modified, or abandoned because of cost. Procedures such as ridge augmentation, guided bone regeneration, and soft-tissue regeneration are well established and science-based, yet the financial burden associated with biomaterials, implants, and reconstruction can place them beyond reach for some patients. The new Geistlich programme aims to help close that gap.

What this means for clinicians

The programme offers clinicians the opportunity to treat patients with a clear regenerative indication without allowing cost to become the determining factor. While support is provided for selected cases, full clinical responsibility remains with the treating clinician, including diagnosis, treatment planning, case execution, and follow-up care. By focusing on predictable, evidence-based regenerative treatment, the initiative supports clinicians in delivering care that is both biologically sound and potentially life-changing for patients who may have previously declined therapy for financial reasons. Only a limited number of cases will be selected worldwide, underscoring the programme's emphasis on careful case review and meaningful patient impact.

How it works

To keep participation efficient, the submission pathway has been structured as a simple two-stage process. The first step consists of a short, anonymised application that includes a brief case overview, key clinical details, and the proposed treatment plan. This initial review allows cases to be assessed without requiring full documentation at the outset. If a case is selected, the second stage requires complete documentation, including patient consent, confirmation of eligibility, and relevant clinical records. This approach is intended to reduce administrative burden while ensuring that selected cases are supported by thorough and appropriate documentation before final approval.

Eligibility and support

The programme is open to licensed dentists and specialists in their respective countries who are committed to evidence-based regenerative treatment. Suitable patient cases must present a clear clinical indication for regenerative therapy, have a history of treatment being declined due to financial constraints, and offer the potential for a predictable clinical outcome.

Selected cases will receive full coverage of Geistlich biomaterials, along with a 50 per cent contribution toward implant costs and a 50 per cent contribution toward crown costs. Professional fees remain the responsibility of the treating clinician.

What makes a strong application?

Applications are expected to demonstrate a meaningful opportunity to improve a patient's condition through regenerative treatment that might not otherwise be possible. Strong submissions typically include a clearly defined regenerative indication, a predictable treatment concept using Geistlich biomaterials, and high-quality clinical documentation such as radiographs and photographs.

Cases involving ridge augmentation, guided bone regeneration, or soft-tissue regeneration are particularly well aligned with the aims of the programme. Clinicians with experience in regenerative procedures and a structured approach to documentation are especially well positioned to contribute strong applications.

A jubilee initiative with clinical and human impact

With this programme, Geistlich is linking its anniversary celebration to a practical effort to improve patient access to advanced regenerative care. The initiative highlights not only the clinical value of regenerative dentistry, but also its potential to address unmet need when financial barriers stand in the way of treatment.

By supporting selected cases around the world, the programme reinforces the importance of combining scientific rigour with patient-centered action. In doing so, it offers a timely example of how industry-supported initiatives can help extend the benefits of modern regenerative therapy to those who need it most.

Contact address
Geistlich Pharma AG
www.geistlich.com